Clik here to view.
Walgreens Boots Alliance Announces Launch of Flagship Store on Alibaba...
DEERFIELD, Ill. & HANGZHOU, China Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Alibaba Group Holding Ltd. (“Alibaba”) (NYSE: BABA) today announced the launch of a Boots flagship store on...
View ArticleClik here to view.
Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI®...
CASTRES, France Pierre Fabre today announced that the European Commission (EC) has granted marketing authorisation for the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for the...
View ArticleClik here to view.
盟科医药宣布Contezolid和Contezolid acefosamil获得美国FDA的QIDP和Fast Track认定
加州福斯特城和中国上海 (美国商业资讯)– 盟科医药今天宣布美国食品药品监督管理局（FDA）授予contezolid（MRX-I）和其前药contezolid acefosamil (MRX-4)用于治疗急性细菌皮肤和皮肤组织感染（ABBSSI）的合格感染疾病产品（QIDP）和快速审评（fast track）认定。...
View ArticleClik here to view.
AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a global regenerative medicine company, today announced that the U.S. Food and Drug Administration (FDA) approved...
View ArticleClik here to view.
首例神经母细胞瘤患者成功接受采用自然杀伤T细胞（CAR-NKT）的创新型CAR疗法
休斯顿&伦敦 Cell Medica公布了世界上首例对患有神经母细胞瘤的儿童进行CMD-501治疗（一种自体CAR-NKT疗法）。首次实现了在人体应用工程NKT细胞疗法。Cell Medica是一家临床阶段性的生物制药公司，通过开发新一代的CAR疗法改变实体瘤和血液瘤的治疗方法。 Cell...
View ArticleClik here to view.
SanBio: Supplementary Information to the Notice Regarding an Equity and...
TOKYO SanBio Co., Ltd. (representative: Keita Mori, headquarters: Chuo-ku, Tokyo; hereinafter SanBio) has agreed to enter into an equity and business alliance with CareNet, Inc. (representative:...
View ArticleClik here to view.
SanBio: Notice Regarding an Equity and Business Alliance Between Five...
TOKYO SanBio Co., Ltd. (representative: Keita Mori, headquarters: Chuo-ku, Tokyo; hereinafter SanBio) hereby announces that it has resolved to enter into an equity and business alliance (hereinafter...
View ArticleClik here to view.
MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for...
FOSTER CITY, Calif. & SHANGHAI MicuRx Pharmaceuticals, Inc. today announced the receipt of the qualified infectious disease product (QIDP) classification and grant of fast track status by the...
View ArticleClik here to view.
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan...
BOTHELL, Wash. Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval from the Japanese Ministry of...
View ArticleClik here to view.
Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab)...
BOSTON Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced positive topline results from the Phase 3 PREVENT study of Soliris® (eculizumab) in patients with anti-aquaporin-4 (AQP4) auto...
View ArticleClik here to view.
British Biologicals’ USA Leadership Team Equipped for Launch of NEW...
EASTVALE, Calif. Equipped with knowledge and backed by rich industry experience, British Biologicals, an award-winning global nutraceutical company, has announced Bharath Reddy, Director of...
View ArticleClik here to view.
WIPOとIFPMAが医療関係者の適切な医薬品の調達に貢献する 新しいオンライン特許情報データベースを開設
ジュネーブ WIPOと研究開発型製薬会社・団体で構成される製薬業界は、医療関係者が世界中の医薬品の特許状況について把握できるよう、提携して新しいオンラインデータベースを開設しました。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。： https://www.businesswire.com/news/home/20180925005096/ja/...
View ArticleClik here to view.
产权组织和IFPMA发布新的在线专利检索资源，帮助卫生机构采购药品
日内瓦 产权组织和研究型制药行业今天推出了一个新的在线工具，旨在帮助采购机构更好地了解全球药品的专利状况。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20180925005093/zh-CN/...
View ArticleClik here to view.
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial,...
View ArticleClik here to view.
Evaluate Ltd: Worldwide medtech Sales Forecast to Reach $595 Billion by 2024,...
LONDON & BOSTON & TOKYO The global medtech industry is forecast to grow at a CAGR of 5.6% from 2017 to 2024 and reach $595 billion in sales by 2024, according to the latest report from...
View ArticleClik here to view.
AVITA Medical Announces Receipt of $1 Million Research and Development Tax...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax...
View ArticleClik here to view.
PeptiDream Announces Drug Discovery and Development Agreement with Santen...
KAWASAKI, Japan PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a broad-based multi-target discovery and...
View ArticleClik here to view.
Konica Minolta Launches Dedicated Precision Medicine Business in Japan
TOKYO Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902) (ISIN: JP3300600008) today announced the launch of Konica Minolta Precision Medicine Japan, Inc. (“KMPMJ”) which will start operations on...
View ArticleClik here to view.
武田收到CHMP肯定意见，推荐ALUNBRIG® (brigatinib)用于治疗既往用过克唑替尼的ALK+非小细胞肺癌患者
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502)今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)已采纳一项肯定意见，推荐全面核准ALUNBRIG®...
View ArticleClik here to view.
Samsung Bioepis’ Biologics License Application for SB5 Adalimumab Biosimilar...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) under the 351(k)...
View Article